CN105101963A - 用于阿兹海默氏病治疗方法中的解旋酶-引发酶抑制剂 - Google Patents

用于阿兹海默氏病治疗方法中的解旋酶-引发酶抑制剂 Download PDF

Info

Publication number
CN105101963A
CN105101963A CN201480008550.6A CN201480008550A CN105101963A CN 105101963 A CN105101963 A CN 105101963A CN 201480008550 A CN201480008550 A CN 201480008550A CN 105101963 A CN105101963 A CN 105101963A
Authority
CN
China
Prior art keywords
methyl
hsv
suffering
acetamide
thiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480008550.6A
Other languages
English (en)
Chinese (zh)
Inventor
露特·伊扎克伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aicuris GmbH and Co KG
Original Assignee
Aicuris GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris GmbH and Co KG filed Critical Aicuris GmbH and Co KG
Publication of CN105101963A publication Critical patent/CN105101963A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN201480008550.6A 2013-02-12 2014-02-12 用于阿兹海默氏病治疗方法中的解旋酶-引发酶抑制剂 Pending CN105101963A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13154982 2013-02-12
EP13154982.6 2013-02-12
PCT/EP2014/052743 WO2014124978A2 (en) 2013-02-12 2014-02-12 Helicase-primase inhibitors for use in a method of treating alzheimer's disease

Publications (1)

Publication Number Publication Date
CN105101963A true CN105101963A (zh) 2015-11-25

Family

ID=47709982

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480008550.6A Pending CN105101963A (zh) 2013-02-12 2014-02-12 用于阿兹海默氏病治疗方法中的解旋酶-引发酶抑制剂

Country Status (16)

Country Link
US (1) US20150374676A1 (https=)
EP (1) EP2956134A2 (https=)
JP (1) JP2016507546A (https=)
KR (1) KR20150119089A (https=)
CN (1) CN105101963A (https=)
AU (1) AU2014217962A1 (https=)
BR (1) BR112015019220A2 (https=)
CA (1) CA2898798A1 (https=)
CL (1) CL2015002241A1 (https=)
EA (1) EA201500836A1 (https=)
IL (1) IL240459A0 (https=)
MX (1) MX2015010339A (https=)
PH (1) PH12015501762A1 (https=)
SG (1) SG11201506153TA (https=)
WO (1) WO2014124978A2 (https=)
ZA (1) ZA201505243B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2573085A1 (en) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
AR110251A1 (es) * 2016-11-28 2019-03-13 Aicuris Anti Infective Cures Gmbh Una sal maleato de la base libre de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, formulaciones farmacéuticas, métodos de fabricación y usos de la misma
US11439608B2 (en) 2017-09-25 2022-09-13 Qun Lu Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease
TW202038947A (zh) * 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
JP7720044B2 (ja) 2020-11-19 2025-08-07 グリアセルテック・インコーポレイテッド ジダノシンを含む神経炎症性疾患の予防または治療用組成物
IL319024A (en) * 2022-08-29 2025-04-01 Assembly Biosciences Inc Pharmaceutical preparations for the herpes virus

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1434812A (zh) * 1999-12-23 2003-08-06 拜尔公司 噻唑基酰胺衍生物
CN101151019A (zh) * 2005-03-30 2008-03-26 艾库里斯有限及两合公司 N-[5-(氨基磺酰基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)苯基]乙酰胺的药物制剂
WO2013045491A1 (en) * 2011-09-26 2013-04-04 Aicuris Gmbh & Co. Kg N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299059B2 (en) * 2009-10-30 2012-10-30 Eli Lilly And Company Crystalline compound and a process for its preparation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1434812A (zh) * 1999-12-23 2003-08-06 拜尔公司 噻唑基酰胺衍生物
CN101151019A (zh) * 2005-03-30 2008-03-26 艾库里斯有限及两合公司 N-[5-(氨基磺酰基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)苯基]乙酰胺的药物制剂
WO2013045491A1 (en) * 2011-09-26 2013-04-04 Aicuris Gmbh & Co. Kg N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MATTHEW A. WOZNIAK ET AL: "Antiviral agents in Alzheimer’s disease: hope for the future?", 《THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS》 *

Also Published As

Publication number Publication date
JP2016507546A (ja) 2016-03-10
MX2015010339A (es) 2015-11-16
WO2014124978A2 (en) 2014-08-21
US20150374676A1 (en) 2015-12-31
BR112015019220A2 (pt) 2017-07-18
EP2956134A2 (en) 2015-12-23
EA201500836A1 (ru) 2016-02-29
PH12015501762A1 (en) 2015-11-09
WO2014124978A4 (en) 2014-12-24
IL240459A0 (en) 2015-09-24
ZA201505243B (en) 2017-11-29
CL2015002241A1 (es) 2016-02-19
WO2014124978A3 (en) 2014-10-30
CA2898798A1 (en) 2014-08-21
KR20150119089A (ko) 2015-10-23
SG11201506153TA (en) 2015-09-29
AU2014217962A1 (en) 2015-09-17

Similar Documents

Publication Publication Date Title
Garg et al. Subacute sclerosing panencephalitis
Whitley et al. Herpes simplex: encephalitis children and adolescents
CN105101963A (zh) 用于阿兹海默氏病治疗方法中的解旋酶-引发酶抑制剂
Forsberg et al. High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters
WO2021234097A1 (en) Mek-inhibitors for the treatment or prevention of coronavirus infections and/or covid-19 cytokine storm
ES2539602T3 (es) Derivado de quinona 2,3-dimetoxi-5-metil-6-(10-hidroxidecil)-1,4-benzoquinona para el tratamiento de esclerosis múltiple progresiva primaria
JP2016528251A (ja) Ｈｅｒ２増幅性癌の処置のための方法
JP2009531405A (ja) チオニニウム化合物およびその使用
US12161633B2 (en) Use of riluzole prodrugs to treat alzheimer's disease
WO2014134569A1 (en) Compositions and methods for treating amyotrophic lateral sclerosis in responders
ES2894801T3 (es) Agente para prevenir y/o tratar la enfermedad de Alzheimer
Bai et al. Multicenter, randomized controlled, open label evaluation of the efficacy and safety of arbidol hydrochloride tablets in the treatment of influenza-like cases
CA3141279A1 (en) Inhibitor combinations for treatment of diseases related to dux4 expression
IL262957B1 (en) 6-fluoro-tropisetron and pharmaceutical formulation comprising it for mitigating amyloid- related diseases
CN109562280B (zh) 复发-缓解型多发性硬化的诊断或预测因子
WO2022155564A1 (en) Use of riluzole prodrugs to treat alzheimer's disease
BR112019021898A2 (pt) Inibidores da protease de zika vírus e métodos de uso dos mesmos
Klein et al. Microglia activation, herpes infection, and NMDA receptor inhibition: common pathways to psychosis?
Steiner et al. Herpes simplex viruses
JP2022523028A (ja) 特発性肺線維症を処置するための方法
Lee et al. Progressive multifocal leukoencephalopathy in an AIDS patient
WO2025253179A1 (en) Brincidofovir for reducing infectious polyomavirus production
CN121398833A (zh) 使用ws365治疗阿尔茨海默病
Venkitakrishnan et al. Drug Corner Baricitinib: Delineating a New Treatment Option in COVID-19
CN121774971A (zh) 汉防己甲素在制备抗伪狂犬病毒药物中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20151125

WD01 Invention patent application deemed withdrawn after publication